Healthy
Conditions
Brief summary
Study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 44847 in Japanese healthy volunteers
Interventions
DRUGBI 44847
DRUGPlacebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
20 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects will be healthy male volunteers who meet the criteria below: * Persons without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure, pulse rate, and body temperature), 12-lead ECG, and laboratory test results * Persons who are 20 or older and 35 or younger * Persons with a BMI 18.5 kg/m2 or more and 25.0 kg/m2 less * Persons who are willing to participate in this trial before study initiation and who give their written consent in accordance with Good Clinical Practice
Exclusion criteria
* Any finding of the medical examination (including BP, Pulse Rate (PR) and ECG) deviating from normal and of clinical relevance * Any evidence of a clinically relevant concomitant disease * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * History of relevant orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) * Intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial * Use of any drugs within 10 days prior to administration or during the trial * Participation in another trial with an investigational drug within four months prior to administration or during the trial * Smoker (\>10 cigarettes or \>3 cigars or \>3 pipes/day) * Inability to refrain from smoking on trial days * Alcohol abuse (more than 60 g/day) * Drug abuse * Blood donation (more than 100 mL) within four weeks prior to administration or during the trial * Excessive physical activities (within one week prior to administration or during the trial) * Any laboratory value outside the reference range that is of clinical relevance * Inability to comply with dietary regimen of study centre 19. A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) * The use of concomitant medications that prolong the QT/QTc interval * Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval \>120 ms * Elevated urinary glucose levels at screening (\>15 mg/dl)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with clinically relevant changes in vital signs | up to day 7 |
| Number of patients with clinically relevant finding in 12-lead electrocardiogram (ECG) | up to day 7 |
| Number of patients with clinically relevant changes in laboratory parameters | up to day 7 |
| Number of patients with adverse events | up to 5 weeks |
Secondary
| Measure | Time frame |
|---|---|
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) | up to 48 hours after drug administration |
| λz (terminal rate constant in plasma) | up to 48 hours after drug administration |
| t1/2 (terminal half-life of the analyte in plasma | up to 48 hours after drug administration |
| MRTpo (mean residence time of the analyte in the body after po administration) | up to 48 hours after drug administration |
| CL/F (total clearance of the analyte in the plasma after extravascular administration) | up to 48 hours after drug administration |
| Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) | up to 48 hours after drug administration |
| Cmax (maximum concentration of the analyte in plasma) | up to 48 hours after drug administration |
| fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2) | up to 48 hours after drug administration |
| CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) | up to 48 hours after drug administration |
| Area under the plasma glucose concentration time curve | up to 12 hours after drug administration |
| Total amount of glucose excreted in the urine | up to 48 hours after drug administration |
| Maximum glucose concentration in plasma | up to 12 hours after drug administration |
| Maximum glucose concentration in urine | up to 48 hours after drug administration |
| Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2) | up to 48 hours after drug administration |
| tmax (time from dosing to maximum concentration) | up to 48 hours after drug administration |
| AUC0-inf. (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | up to 48 hours after drug administration |
| %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation) | up to 48 hours after drug administration |
Outcome results
None listed